Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer

Journal of Clinical Oncology

Volumn 33, Issue 25, 2015, Pages 2789-2796

  Yamoah, Kosj ^a,c   Johnson, Michael H ^a   Choeurng, Voleak ^e   Faisal, Farzana A ^d   Yousefi, Kasra ^e   Haddad, Zaid ^e   Ross, Ashley E ^d   Alshalafa, Mohammed ^e   Den, Robert ^a   Lal, Priti ^b   Feldman, Michael ^b,d   Dicker, Adam P ^a   Klein, Eric A ^f   Davicioni, Elai ^e   Rebbeck, Timothy R ^b   Schaeffer, Edward M ^d  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e GenomeDx Biosciences Inc   (Canada)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMACR PROTEIN; ANDROGEN RECEPTOR; BETA MICROSEMINOPROTEIN; BIOLOGICAL MARKER; CYTOCHROME P450 3A4; FOLH1 PROTEIN; FOXP1 PROTEIN; GLUTATHIONE TRANSFERASE P1; GOLM1 PROTEIN; MESSENGER RNA; MKI67 PROTEIN; MYCBP PROTEIN; NKX3 1 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN P53; PROTEIN P63; RB1 PROTEIN; SPINK1 PROTEIN; SPOP PROTEIN; STEROID 5ALPHA REDUCTASE 2; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR EZH2; TUMOR MARKER; UNCLASSIFIED DRUG; ALPHA-METHYLACYL-COA RACEMASE; CARRIER PROTEIN; ERG PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; GOLM1 PROTEIN, HUMAN; GSTP1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; ISOMERASE; MEMBRANE PROTEIN; NKX3-1 PROTEIN, HUMAN; REPRESSOR PROTEIN; RETINOBLASTOMA PROTEIN; SPINK1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER GROWTH; CLINICAL FEATURE; COHORT ANALYSIS; ETHNIC DIFFERENCE; ETHNIC GROUP; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; CANCER STAGING; CAUCASIAN; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; EPIDEMIOLOGY; ETHNOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROSTATE TUMOR; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

AFRICAN AMERICANS; AGED; BIOMARKERS, TUMOR; CARRIER PROTEINS; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; HOMEODOMAIN PROTEINS; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; RECEPTORS, ANDROGEN; REPRESSOR PROTEINS; RETINOBLASTOMA PROTEIN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL REGULATOR ERG; UNITED STATES;

EID: 84941354031     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.8912     Document Type: Article

References (48)

1. Jemal A, Center MM, DeSantis C, et al: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893-1907, 2010
2. American Cancer Society: Cancer Facts and Figures for African Americans, 2007-2008. Atlanta, GA, American Cancer Society, 2007
3. Albain KS, Unger JM, Crowley J.J., et al: Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 101:984-992, 2009
4. Haiman CA, Chen GK, Blot W.J., et al: Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet 7:e1001387, 2011
5. Kerns SL, Ostrer H, Stock R., et al: Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 78:1292-1300, 2010
6. Perner S, Hofer MD, Kim R, et al: Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696-701, 2007
7. Perner S, Mosquera JM, Demichelis F, et al: TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 31:882-888, 2007
8. Berney DM, Gopalan A, Kudahetti S., et al: Ki-67 and outcome in clinically localized prostate cancer: Analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 100:888-893, 2009
9. Li R, Wheeler T, Dai H., et al: High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: Cancer patients treated with radical prostatectomy. Am J Surg Pathol 28:928-934, 2004
10. Attard G, Clark J, Ambroisine L., et al: Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27:253-263, 2008
11. Fine SW, Gopalan A, Leversha M.A., et al TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 23:1325-1333, 2010
12. Bjartell AS, Al-Ahmadie H, Serio A.M., et al Association of cysteine-rich secretory protein 3 and /3-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 13:4130-4138, 2007
13. LeeWH, Morton RA, Epstein JI, et al: Cytidine methylation of regulatory sequences near the piclass glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91:11733-11737, 1994
14. Erho N, Buerki C, Triche T.J., et al Transcriptome-wide detection of differentially expressed coding and non-coding transcripts and their clinical significance in prostate cancer. J Oncol 2012:541353, 2012
15. Den RB, Yousefi K, Trabulsi E.J., et al: Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol 33:944-951, 2015
16. Klein EA, Yousefi K, Haddad Z., et al: A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol 67:778-786, 2015
17. Cooperberg MR, Hilton JF, Carroll PR: The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117:5039-5046, 2011
18. Edge SB, Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471-1474, 2010
19. Den RB, Feng FY, Showalter T.N., et al Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys 89:1038-1046, 2014
20. Taylor BS, Schultz N, Hieronymus H., et al Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11-22, 2010
21. Sundi D, Ross AE, Humphreys E.B., et al: African American men with very-low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: Should active surveillance still be an option for them? J Clin Oncol 31:2991-2997, 2013
22. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al: A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 66:550-560, 2014
23. Erho N, Crisan A, Vergara I.A., et al: Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 8:e66855, 2013
24. Tomlins SA, Alshalalfa M, Davicioni E., et al: Characterization of 1,577 primary prostate cancers reveals novel biological and clinical insights into molecular subtypes. Eur Urol 10.1016/j.eururo.2015.04.033 [epub ahead of print on May 15, 2015]
25. Penney KL, Sinnott JA, Fall K, et al: mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol 29:2391-2396, 2011
26. Cuzick J, Berney DM, Fisher G, et al: Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106:1095-1099, 2012
27. Karnes RJ, Bergstralh EJ, Davicioni E, et al: Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 190:2047-2053, 2013
28. Petrovics G, Liu A, Shaheduzzaman S., et al: Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24:3847-3852, 2005
29. Mosquera JM, Mehra R, Regan M.M., et al: Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 15:4706-4711, 2009
30. Magi-Galluzzi C., Tsusuki T, Elson P., et al: TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American, and Japanese patients. Prostate 71:489-497, 2011
31. Hu Y, Dobi A, Sreenath T., et al: Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 14:4719-4725, 2008
32. Kunju LP, Chinnaiyan AM, Shah RB: Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer. Histopathology 47:587-596, 2005
33. Zhou M, Aydin H, Kanane H., et al: How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol 28:239-243, 2004
34. Sharma A, Yeow WS, Ertel A, et al: The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 120:4478-4492, 2010
35. Takayama K, Horie-Inoue K, Ikeda K., et al: FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. Biochem Biophys Res Commun 374:388-393, 2008
36. Bowen C, Bubendorf L, Voeller H.J., et al: Loss of NKX3-1 expression in human prostate cancers correlates with tumor progression. Cancer Res 60: 6111-6115, 2000
37. Paju A, Hotakainen K, Cao Y., et al: Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer, and in androgen-independent 22Rv1 cells. Eur Urol 52:1670-1679, 2007
38. Tomlins SA, Rhodes DR, Yu J, et al: The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13:519-528, 2008
39. Varambally S, Laxman B, Mehra R., et al: Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 10:1285-1294, 2008
40. Gaston KE, Kim D, Singh S., et al: Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 170:990-993, 2003
41. Kudahetti S, Fisher G, Ambroisine L., et al: p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU Int 104:20-24, 2009
42. Trink B, Okami K, Wu L., et al: A new human p53 homologue. Nat Med 4:747-748, 1998
43. Signoretti S, Waltregny D, Dilks J., et al: P63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769-1775, 2000
44. Fisher G, Yang ZH, Kudahetti S, et al: Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort. Br J Cancer 108: 271-277, 2013
45. Thomas G, Jacobs KB, Yeager M, et al: Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40:310-315, 2008
46. Eeles RA, Kote-Jarai Z, Giles G.G., et al: Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40:316-321, 2008
47. Zeigler-Johnson C.M., Walker AH, Mancke B, et al: Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 54:13-21, 2002
48. Rebbeck TR, Halbert CH, Sankar P: Genetics, epidemiology, and cancer disparities: Is it black and white? J Clin Oncol 24:2164-2169, 2006